Both 6-month trials were randomized, controlled studies that evaluated PER-001 delivered in a slow-release, dissolvable ...

The REMS program for the ERA drug class was established due to the risk of embryofetal toxicity seen from animal studies.

Endothelin (ET) is a 21-amino acid peptide that is produced by endothelial cells after processing from preproendothelin, its precursor molecule (Figure 1).

In this Healio Video Perspective from Clinical Trials at the Summit, Arshad M. Khanani, MD, MA, FASRS, highlights first-time ...

Dublin, March 04, 2025 (GLOBE NEWSWIRE) -- The "Endothelin Receptor Antagonist - Pipeline Insight, 2025" clinical trials has been added to ResearchAndMarkets.com's offering. This report provides ...

Are selective endothelin-receptor antagonists really an important new advance for treating patients with treatment-resistant hypertension? The evidence from a recent study leaves us with some ...

Endothelin, a chain of amino acids that is produced by endothelial and other cell types, can bind to these receptors on smooth muscle cells to control how much they constrict and dilate.

CHICAGO — Aprocitentan, a dual endothelin antagonist, was superior to placebo for BP lowering and was well tolerated in patients with resistant hypertension, according to results of the ...

US FDA approves Idorsia’s once-daily TRYVIO (aprocitentan) – the first and only endothelin receptor antagonist for the treatment of high blood pressure not adequately controlled in combination ...

SHANGHAI, July 8, 2024 /PRNewswire/ -- BioCity Biopharma (BioCity) announced its endothelin receptor type A (ETA) selective antagonist SC0062 met the primary endpoint of proteinuria reduction in the 2 ...